- Home
- BP vs PFE Comparison
BP vs PFE Comparison
Compare BP & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BP | PFE |
|---|---|---|
| Founded | 1889 | 1849 |
| Country | United Kingdom | United States |
| Employees | 93700 | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.3B | 147.6B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BP | PFE |
|---|---|---|
| Price | $39.40 | $24.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $44.43 | $29.29 |
| AVG Volume (30 Days) | 9.0M | ★ 28.3M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | 4.18% | ★ 6.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $62,579,000,000.00 |
| Revenue This Year | $13.52 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11,332.35 | ★ $53.34 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.58 | $23.11 |
| 52 Week High | $48.27 | $28.75 |
Technical Indicators
Market Signals| Indicator | BP | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 32.10 | 33.94 |
| Support Level | $33.30 | $23.96 |
| Resistance Level | $39.51 | $24.88 |
| Average True Range (ATR) | 0.82 | 0.45 |
| MACD | -0.33 | -0.07 |
| Stochastic Oscillator | 12.05 | 0.87 |
Price Performance
Historical ComparisonAbout BP BP p.l.c.
BP is an integrated energy company that explores for, produces, and refines oil and gas around the world. In 2025, it produced 1.2 million barrels of liquids and 6.5 billion cubic feet of natural gas per day. At the end of 2025, proved hydrocarbon reserves stood at 6.2 billion barrels of oil equivalent, 56% of which are liquids. The company operates refineries with a total crude distillation capacity of 1.56 million barrels of oil per day.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.